Precision Senotherapeutics Map

Beyond D+Q — Three Frontiers of Next-Generation Senolytic Strategy
Zhang W et al. · NPJ Aging 2026 DOI: 10.1038/s41514-026-00355-z PMID: 41807411

The Shift to Precision Senotherapy

Cellular senescence drives aging and age-related disease through chronic SASP-mediated inflammation and immune evasion. First-generation senolytics (D+Q, navitoclax) proved the concept but suffer from thrombocytopenia, variable efficacy, and resistance. Three next-generation strategies now promise precision: immune-based senolysis, tissue-specific PROTACs, and microbiome-epigenetic modulation.

3
Next-Gen Strategies
12+
Surface Markers
8
Diseases Targeted
5
Clinical Trials

Evolution from Broad Senolysis to Precision Reprogramming

FIRST GENERATION NEXT GENERATION FUTURE Broad-Spectrum D+Q · Navitoclax · Fisetin ⚠ Thrombocytopenia ⚠ Variable efficacy ⚠ Resistance emergence 🛡 Immune Senolysis Anti-uPAR CAR-T cells GD3 immune checkpoint blockade Ferroptosis / glutaminolysis Amor et al. Nature 2020 · Nat Aging 2024, 2026 🎯 Tissue PROTACs VHL E3 ligase recruitment BCL-xL selective degradation Organ-specific delivery He et al. Mol Cell 2023 · Khan et al. Nat Chem Biol 2024 🦠 Microbiome Axis Butyrate / SCFA modulation Drug transporter epigenetics SASP suppression via gut-liver Gut-liver axis · dietary synergy Precision Senotherapy Personalized · Targeted Vision 2030+ Combination regimens Biomarker-guided dosing schedules AI-predicted SnC heterogeneity maps Reprogramming without removal
STRATEGY 1

Immune-Based Senolysis

Harness the immune system to selectively eliminate senescent cells. CAR-T cells target uPAR+ senescent cells; anti-GD3 immunotherapy blocks senescence immune checkpoints; metabolic vulnerabilities (ferroptosis, glutaminolysis) sensitize SnCs to immune clearance.

uPAR GD3 GPX4 GLS1 NK cells
STRATEGY 2

Tissue-Precision PROTACs

Proteolysis-targeting chimeras recruit tissue-specific E3 ligases (VHL) to selectively degrade anti-apoptotic BCL-xL in senescent cells. Localized activity avoids systemic platelet toxicity seen with navitoclax. Represents pharmacology's answer to cell therapy.

BCL-xL VHL CRBN PZ-15227 DT2216
STRATEGY 3

Microbiome-Epigenetic Axis

The gut-liver axis modulates senolytic efficacy through epigenetic reprogramming. SCFAs like butyrate regulate drug transporter expression and suppress SASP. Dietary interventions create a microenvironment favorable to senolysis — the least invasive strategy.

Butyrate SCFA HDAC SASP Gut-liver

Strategy Comparison — Key Dimensions

Senotherapeutic Evolution Timeline

Cellular Senescence — The Aging Driver

Cellular senescence is a state of irreversible growth arrest characterized by morphological changes, chromatin reorganization, metabolic reprogramming, and secretion of the senescence-associated secretory phenotype (SASP). While initially protective against cancer, senescent cell accumulation with age drives chronic inflammation and tissue dysfunction.

1961
Hayflick Limit Discovery
~50
SASP Factors Identified
12+
Surface Markers
8+
Induction Pathways

Senescent Cell — Hallmark Features & SASP Cascade

SENESCENT CELL 🔴 p16ᴵᴺᴷ⁴ᵃ / p21 activation 🧬 DNA damage foci (γH2AX) 🔋 Mitochondrial dysfunction 📏 Enlarged, flattened morphology 🛡 BCL-xL/BCL-2 pro-survival 🎭 SA-β-Gal activity Surface: uPAR · GD3 · DPP4 · B2M SASP Secretory Phenotype Cytokines IL-6, IL-8, IL-1α/β, TNF-α Chemokines CCL2, CCL5, CXCL1, CXCL10 Proteases MMP-1, MMP-3, MMP-9 Growth Factors TGF-β, VEGF, PDGF, HGF Extracellular Vesicles Exosomes, microvesicles Lipids & ROS PGE2, reactive oxygen species Chronic Inflammation Tissue Fibrosis Stem Cell Exhaustion Paracrine Senescence Immune Dysregulation TRIGGERS Telomere attrition · Oncogene activation · DNA damage · Oxidative stress · Mitotic stress · Epigenetic · Therapy-induced

Key Senescence Surface Markers — Therapeutic Targets

MarkerFull NameExpressionTherapeutic ApproachEvidence
uPARUrokinase Plasminogen Activator Receptor ↑↑↑ on senescent fibroblasts, HSCs, macrophages CAR-T
90%
GD3Disialylated Ganglioside ↑↑ on aged liver, lung, kidney, bone cells Anti-GD3 mAb
75%
BCL-xLB-Cell Lymphoma-extra Large ↑↑↑ anti-apoptotic; core survival dependency PROTAC
85%
DPP4Dipeptidyl Peptidase 4 ↑ on senescent fibroblasts Ab-mediated
55%
GPX4Glutathione Peroxidase 4 Ferroptosis defense dependency Ferroptosis
60%
GLS1Glutaminase 1 ↑↑ glutamine dependency for pH homeostasis Glutaminolysis
65%
B2MBeta-2 Microglobulin ↑ surface MHC-I; NK evasion Immune mod.
45%

Senescent Cell Burden by Tissue

First-Generation Senolytics — Proof of Concept & Limitations

D+Q (Dasatinib + Quercetin) and ABT-263 (Navitoclax) established that selective senescent cell removal can reverse fibrotic, metabolic, and cardiovascular pathologies. But systemic toxicity and resistance demanded a new paradigm.

Dasatinib + Quercetin (D+Q)

GEN 1 · 2015
  • 🎯Dasatinib: tyrosine kinase inhibitor (Src, c-Abl, ephrin)
  • 🍃Quercetin: flavonoid; PI3K/AKT, BCL-2/xL, p53/serpine
  • ✅First-in-human: diabetic kidney disease (Hickson 2019)
  • ✅IPF open-label pilot (Justice 2019)
  • ✅Postmenopausal bone (Farr 2024, Phase 2 RCT)
  • ⚠️Variable efficacy across tissue types
  • ⚠️Non-specific kinase inhibition → off-target effects

Navitoclax (ABT-263)

GEN 1 · 2016
  • 🎯BH3 mimetic: inhibits BCL-2, BCL-xL, BCL-W
  • ✅Rejuvenates aged HSCs in mice (Chang 2016)
  • ✅Strong senolytic in fibroblasts & epithelial cells
  • ❌Severe thrombocytopenia — platelets depend on BCL-xL
  • ❌Dose-limiting toxicity in Phase 1 oncology trials
  • ⚠️Cannot be used systemically for aging
  • 💡Inspired galacto-conjugation (Nav-Gal) & PROTAC approaches

Why First-Gen Falls Short — The Resistance Problem

LimitationMechanismNext-Gen Solution
ThrombocytopeniaBCL-xL inhibition kills plateletsTissue PROTAC
Variable efficacySnC heterogeneity across tissuesMarker-directed
Resistance emergenceBCL-2→MCL-1 switching; SASP evolutionMulti-target
Off-target kinase effectsDasatinib hits >30 kinasesProtein degradation
Poor bioavailabilityQuercetin ~1-2% oral absorptionMicrobiome enhance
Immune evasion unaddressedSnCs upregulate GD3, PDL1Checkpoint block

Strategy 1 — Immune-Based Senolysis

Borrowing from immuno-oncology, this strategy uses the immune system as a precision senolytic weapon. Three complementary approaches: CAR-T cells targeting uPAR, checkpoint blockade of GD3-mediated immune evasion, and metabolic exploitation of ferroptosis/glutaminolysis vulnerability.

Immune Senolysis — Three Attack Vectors

Senescent Cell uPAR⁺ · GD3⁺ · BCL-xL⁺ GLS1⁺ · GPX4-dep 🔬 Anti-uPAR CAR-T Amor et al. Nature 2020 • Prophylactic: prevents metabolic dysfunction (Nat Aging 2024) • Intestinal regeneration restored (Nat Aging 2026 Eskiocak) In vivo mRNA LNP delivery 🛡 GD3 Checkpoint Blockade Iltis et al. Nat Aging 2025 • GD3 = senescence immune checkpoint (SIC) • Suppresses NK cell degranulation • Anti-GD3 Ab: ↓ liver/lung fibrosis Analogous to anti-PD1 in oncology ⚡ Metabolic Vulnerability Ferroptosis & Glutaminolysis • GLS1 inhibition → acidic pH → death • GPX4 dependency → ferroptosis-prone • Iron accumulation in aged SnCs • Sensitize → immune recognition Metabolic priming for clearance ↓ SELECTIVE ELIMINATION ↓ Tissue Rejuvenation

Anti-uPAR CAR-T

Amor, Sadelain, Lowe Lab · MSKCC/CSHL

  • 🧬uPAR upregulated on senescent fibroblasts, HSCs, macrophages across multiple tissues
  • 💊Single infusion: long-lasting (>6 months in mice) due to T cell memory
  • 🔬Reversed liver fibrosis, metabolic syndrome, adipose dysfunction in old mice
  • 🆕2026: Restores intestinal stem cell fitness and regeneration (Eskiocak et al.)
  • ⚠️Manufacturing complexity ($$$), immunopathology risk, long-term safety unknown

GD3 Checkpoint Blockade

Iltis, Cherfils-Vicini, Gilson · IRCAN Nice

  • 🛡GD3 ganglioside = first senescence immune checkpoint (SIC)
  • 🧬Suppresses NK cell degranulation, prevents immune clearance
  • 📈Increases with age in liver, lung, kidney, bone
  • 💊Anti-GD3 mAb attenuated fibrosis and bone remodeling in aged mice
  • 💡Analogous to anti-PD1/PDL1 in oncology — restores natural immunosurveillance

Metabolic Vulnerabilities

Ferroptosis · Glutaminolysis · pH homeostasis

  • ⚡GLS1 inhibition → intracellular acidification → SnC death
  • 🔩Senescent cells accumulate iron → ferroptosis susceptibility
  • 🧪GPX4 inhibition (RSL3, erastin) selectively kills SnCs
  • 🔄Combines with immune priming: metabolically weakened SnCs more immunogenic
  • ⚠️Systemic ferroptosis risk in healthy tissues with high iron

uPAR CAR-T — Key Preclinical Results

Strategy 2 — Tissue-Precision PROTACs

PROTACs (Proteolysis-Targeting Chimeras) offer a pharmacological solution to navitoclax toxicity. By recruiting tissue-specific E3 ubiquitin ligases like VHL, these bifunctional molecules selectively degrade BCL-xL in senescent cells while sparing platelets — which lack VHL expression.

PROTAC Mechanism — Targeted Protein Degradation

BCL-xL Anti-apoptotic Target Protein PROTAC Bifunctional molecule e.g., DT2216, PZ-15227 warhead ligand VHL E3 Ligase (tissue-specific) Ub Ub Ub BCL-xL ubiquitinated 26S Proteasome BCL-xL degraded → SnC apoptosis KEY ADVANTAGE: VHL is NOT expressed in platelets → BCL-xL degradation occurs in senescent cells but NOT platelets → NO thrombocytopenia

DT2216 — The Pioneer

VHL-BCL-xL PROTAC
  • 🎯First BCL-xL PROTAC; recruits VHL E3 ligase
  • ✅Potent senolytic in human IMR-90 fibroblasts & WI-38 cells
  • ✅Less platelet toxicity than navitoclax in mice
  • ✅Rejuvenated aged HSCs without thrombocytopenia
  • 📊Developed by Zheng/Zhou lab, University of Florida
  • ⚠️IV administration; oral bioavailability limited

PZ-15227 — Next-Gen Oral

CRBN-BCL-xL PROTAC
  • 🎯Uses cereblon (CRBN) E3 ligase instead of VHL
  • ✅Oral bioavailability — practical for aging indications
  • ✅Senolytic in multiple cell types
  • ✅Reduced platelet toxicity profile
  • 📊Better tissue distribution for systemic senolysis
  • ⚠️CRBN broadly expressed → less tissue selectivity than VHL

PROTAC vs Inhibitor — Advantage Comparison

PropertyNavitoclax (Inhibitor)DT2216 (VHL PROTAC)PZ-15227 (CRBN PROTAC)
MechanismBCL-xL occupancy/inhibitionBCL-xL degradation (VHL)BCL-xL degradation (CRBN)
Platelet toxicitySevere (dose-limiting)Minimal (VHL absent)Reduced (CRBN low in PLT)
Catalytic activityStoichiometric (1:1)Catalytic (substoichiometric)Catalytic (substoichiometric)
RouteOralIVOral
Tissue selectivityNone (systemic)VHL-expressing tissuesLess selective (CRBN broad)
Resistance riskBCL-2/MCL-1 switchingLower (removes protein entirely)Lower (removes protein entirely)

Platelet Sparing — PROTAC vs Inhibitor

Strategy 3 — Microbiome-Epigenetic Axis

The gut-liver axis modulates senolytic drug efficacy through epigenetic regulation of drug transporters and SASP suppression. Short-chain fatty acids (SCFAs) like butyrate act as HDAC inhibitors, reprogram gene expression in senescent cells and surrounding tissue, and create a microenvironment favorable to senolysis. This is the least invasive strategy — achievable through dietary intervention.

Gut-Liver-Senescence Axis — Microbiome Modulation of Senolytic Efficacy

🦠 Gut Microbiome Fiber fermentation Butyrate (C₄) Propionate (C₃) Acetate (C₂) Dietary modulation: Fiber · Prebiotics Probiotics · Fermented foods · Resistant starch Portal vein 🫁 Liver SCFA-mediated effects: HDAC inhibition ↑ Drug transporter expression (OAT, OATP, MRP families) NF-κB suppression ↓ Hepatic SASP output ↓ Inflamm-aging cascade ↑ Drug Transporter Expression Enhanced senolytic uptake by target cells Butyrate → HDAC → acetylation → OAT/MRP transcription ↓ SASP Suppression Reduced inflammatory signaling from SnCs SCFAs → GPR43/GPR109A → NF-κB inhibition ↑ Immune Competence Restored immunosurveillance of SnCs Butyrate → Treg/Th17 balance → anti-senescence immunity 💡 Dietary intervention may enhance efficacy of ALL senolytic strategies High-fiber diet + senolytic drug = synergistic senescent cell clearance

Butyrate & HDAC

  • 🧬Class I/II HDAC inhibitor → histone hyperacetylation
  • 📈Upregulates drug transporters (OAT, OATP, MRP) → enhanced senolytic uptake
  • 🔬Modulates cell cycle regulators, apoptotic machinery
  • 🍽Dietary sources: resistant starch, oat bran, legumes

SASP Suppression

  • 🔥SCFAs inhibit NF-κB → ↓ IL-6, IL-8, TNFα secretion
  • 🛡Reduce paracrine senescence spread
  • 🦠GPR43/GPR109A receptor activation → anti-inflammatory signaling
  • 💊Senomorphic effect: suppress SASP without killing SnCs

Gut-Immune Crosstalk

  • 🔄Butyrate promotes Treg differentiation → immune tolerance tuning
  • 🛡Restores NK cell function compromised by dysbiosis
  • 🧬Epigenetic training of macrophages → improved SnC phagocytosis
  • 🍴Mediterranean diet linked to lower senescence burden in epidemiological studies

SCFA Effects on Senolytic Efficacy — Mechanism Map

Strategy Arena — Head-to-Head Comparison

Comparing all three next-generation strategies across clinical readiness, safety, specificity, scalability, and combination potential. No single approach wins on all axes — the future is likely combinatorial.

Property D+Q Navitoclax uPAR CAR-T Anti-GD3 DT2216 PZ-15227 SCFA/Diet
Mechanism Multi-kinase + flavonoid BH3 mimetic Engineered T cells Checkpoint blockade VHL PROTAC CRBN PROTAC Epigenetic modulation
Target Src/PI3K/BCL-2 BCL-2/xL/W uPAR⁺ SnCs GD3 checkpoint BCL-xL (degrade) BCL-xL (degrade) HDAC/NF-κB
Specificity Low Low High High Medium-High Medium Low (adjunctive)
Platelet Safety ✅ Safe ❌ Severe toxicity ✅ Safe ✅ Safe ✅ Spared ✅ Reduced ✅ Safe
Duration Intermittent dosing Continuous dosing >6 months (memory) Repeat infusions Repeat dosing Oral repeat Continuous dietary
Route Oral Oral IV infusion IV/IP injection IV Oral Oral (dietary)
Human Data Phase 1/2 (4 trials) Phase 1 (oncology) Preclinical Preclinical Preclinical Preclinical Epidemiological
Manufacturing Simple (pills) Simple (pills) Complex (per-patient) Moderate (mAb) Complex (synthesis) Moderate (synthesis) Simple (food)
Cost Estimate $<100/course $1K-5K/course $50K-500K $5K-50K $1K-10K $500-5K $<50/month
Combination Potential Moderate Limited (toxicity) High High High High Universal adjunct

Strategy Radar — 6 Dimensions

Clinical Readiness Score

The Combinatorial Future — Synergy Map

Immune CAR-T · GD3 Ferroptosis PROTACs DT2216 PZ-15227 Microbiome SCFA · Diet BCL-xL degrade + immune prime Enhanced immune surveillance via gut ↑ PROTAC uptake via transporters SYNERGY Triple combo Synergy Rationale Immune + PROTAC: Weaken → expose → kill Immune + Micro: Restore NK/T cell fitness PROTAC + Micro: Better drug delivery All three: Maximum precision senotherapy

Senolytic Target Estimator

Estimate the optimal senolytic strategy based on patient/tissue characteristics. Adjust parameters to see which approach scores highest for specificity, safety, and efficacy in different scenarios.

Patient & Tissue Parameters

Presets

Recommended Strategy Scores

References

Key papers driving the precision senotherapeutics revolution.

  1. Zhang W et al. Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming. NPJ Aging (2026). DOI: 10.1038/s41514-026-00355-z
  2. Amor C, Feucht J, Leibold J et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127–132 (2020). DOI: 10.1038/s41586-020-2403-9
  3. Amor C, Fernández-Maestre I et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging 4, 336–349 (2024). DOI: 10.1038/s43587-023-00560-5
  4. Eskiocak O, Gewolb J et al. Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness. Nat Aging 6, 108–126 (2026). DOI: 10.1038/s43587-025-01022-w
  5. Iltis C et al. A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging. Nat Aging 5, 219–236 (2025). DOI: 10.1038/s43587-024-00776-z
  6. Zhang Z, Ma B et al. Cardiolipin-mimic lipid nanoparticles delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med 6, 102209 (2025). DOI: 10.1016/j.xcrm.2025.102209
  7. Zhu Y et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015). DOI: 10.1111/acel.12344
  8. Chang J et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78–83 (2016). DOI: 10.1038/nm.4010
  9. Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of D+Q. EBioMedicine 47, 446–456 (2019). DOI: 10.1016/j.ebiom.2019.08.069
  10. González-Gualda E et al. Galacto-conjugation of navitoclax as an efficient strategy to increase senolytic specificity. Aging Cell 19, e13142 (2020). DOI: 10.1111/acel.13142
  11. McHugh D, Durán I & Gil J. Senescence as a therapeutic target in cancer and age-related diseases. Nat Rev Drug Discov 24, 57–71 (2025). DOI: 10.1038/s41573-024-01074-4
  12. Chaib S, Tchkonia T & Kirkland JL. Cellular senescence and senolytics: the path to the clinic. Nat Med 28, 1556–1568 (2022). DOI: 10.1038/s41591-022-01923-y
  13. Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 24, 1246–1256 (2018). DOI: 10.1038/s41591-018-0092-9
  14. Lin Y, Wang B et al. Integrative omics reveal female-specific benefits of p16+ cell clearance in aging mice. Adv Sci 13, e09444 (2026). DOI: 10.1002/advs.202509444
  15. Farr JN et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 RCT. Nat Med 30, 2605–2612 (2024). DOI: 10.1038/s41591-024-03096-2
  16. Rosas-Campos R et al. Above and beyond senescence and CAR T cell: advances and future perspectives. Front Immunol 16, 1701655 (2025). DOI: 10.3389/fimmu.2025.1701655
  17. Wang B et al. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol 25, 958–978 (2024). DOI: 10.1038/s41580-024-00727-x
  18. Di Micco R, Krizhanovsky V et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 22, 75–95 (2021). DOI: 10.1038/s41580-020-00314-w
  19. Alcon C et al. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Cell Death Differ 32, 646–656 (2025). DOI: 10.1038/s41418-024-01417-z
  20. Ali N et al. beta-Galactosidase-cleavable polymeric senotherapeutics for protein-binding photodynamic senolysis. ACS Macro Lett 15, 60–66 (2026). DOI: 10.1021/acsmacrolett.5c00612